Comparative Pharmacology
Head-to-head clinical analysis: ALTOPREV versus MEVACOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTOPREV versus MEVACOR.
ALTOPREV vs MEVACOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
10-80 mg orally once daily in the evening.
None Documented
None Documented
14 hours (terminal); extended-release formulation allows once-daily dosing
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-CoA reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)